We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why CVS Health (CVS) Outpaced the Stock Market Today
Read MoreHide Full Article
CVS Health (CVS - Free Report) closed the most recent trading day at $44.36, moving +1.32% from the previous trading session. This change outpaced the S&P 500's 1.09% gain on the day. Meanwhile, the Dow gained 1.18%, and the Nasdaq, a tech-heavy index, added 1.03%.
Prior to today's trading, shares of the drugstore chain and pharmacy benefits manager had lost 23.33% over the past month. This has lagged the Retail-Wholesale sector's gain of 3.19% and the S&P 500's loss of 0.71% in that time.
The investment community will be closely monitoring the performance of CVS Health in its forthcoming earnings report. The company is forecasted to report an EPS of $1.04, showcasing a 50.94% downward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $97.27 billion, indicating a 3.69% increase compared to the same quarter of the previous year.
CVS's full-year Zacks Consensus Estimates are calling for earnings of $5.29 per share and revenue of $371.96 billion. These results would represent year-over-year changes of -39.47% and +3.96%, respectively.
Investors might also notice recent changes to analyst estimates for CVS Health. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 2.6% lower. CVS Health presently features a Zacks Rank of #3 (Hold).
Looking at valuation, CVS Health is presently trading at a Forward P/E ratio of 8.27. This denotes a premium relative to the industry's average Forward P/E of 6.17.
Meanwhile, CVS's PEG ratio is currently 0.76. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. By the end of yesterday's trading, the Retail - Pharmacies and Drug Stores industry had an average PEG ratio of 0.76.
The Retail - Pharmacies and Drug Stores industry is part of the Retail-Wholesale sector. Currently, this industry holds a Zacks Industry Rank of 189, positioning it in the bottom 25% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why CVS Health (CVS) Outpaced the Stock Market Today
CVS Health (CVS - Free Report) closed the most recent trading day at $44.36, moving +1.32% from the previous trading session. This change outpaced the S&P 500's 1.09% gain on the day. Meanwhile, the Dow gained 1.18%, and the Nasdaq, a tech-heavy index, added 1.03%.
Prior to today's trading, shares of the drugstore chain and pharmacy benefits manager had lost 23.33% over the past month. This has lagged the Retail-Wholesale sector's gain of 3.19% and the S&P 500's loss of 0.71% in that time.
The investment community will be closely monitoring the performance of CVS Health in its forthcoming earnings report. The company is forecasted to report an EPS of $1.04, showcasing a 50.94% downward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $97.27 billion, indicating a 3.69% increase compared to the same quarter of the previous year.
CVS's full-year Zacks Consensus Estimates are calling for earnings of $5.29 per share and revenue of $371.96 billion. These results would represent year-over-year changes of -39.47% and +3.96%, respectively.
Investors might also notice recent changes to analyst estimates for CVS Health. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 2.6% lower. CVS Health presently features a Zacks Rank of #3 (Hold).
Looking at valuation, CVS Health is presently trading at a Forward P/E ratio of 8.27. This denotes a premium relative to the industry's average Forward P/E of 6.17.
Meanwhile, CVS's PEG ratio is currently 0.76. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. By the end of yesterday's trading, the Retail - Pharmacies and Drug Stores industry had an average PEG ratio of 0.76.
The Retail - Pharmacies and Drug Stores industry is part of the Retail-Wholesale sector. Currently, this industry holds a Zacks Industry Rank of 189, positioning it in the bottom 25% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.